Business
ProtoKinetix’s AAGP® Signs a Material Transfer Agreement with a Reputed International Biotech Company
ProtoKinetix’s AAGP® Signs a Material Transfer Agreement with a Reputed International Biotech Company.
About this update from Protokinetix, Inc.
[{"type":"text","content":"\n \n ProtoKinetix, Incorporated (www.protokinetix.com) \n (the \"Company\" or \"ProtoKinetix\") (OTCQB:PKTX) \n is pleased to announce that it has executed a Material Transfer \n Agreement (MTA) with a reputed biotechnology company having a number of \n worldwide offices on four continents.\n \n \n Under the MTA, ProtoKinetix and this company are working together to \n test the effects AAGP® have on three projects:\n \n \n 1. Cryopreservation of Primary Mammalian Tissue Cells\n \n \n 2. Enhancing the Viability of Primary Mammalian Cells\n \n \n 3. Cell Lines Under Stressed Culture Conditions\n \n \n Before testing a drug in human patients, researchers use primary cells \n from different human donors to verify that the same effects are \n observed. Except for the enzymatic and/or physical dissociation required \n for extracting the cells from their tissue of origin, primary cells are \n not altered in any way. Primary Cell lines are hardy, chiefly because \n they have to last a long time in culture and be capable of surviving \n multiple rounds of cryopreservation and thawing.\n \n \n Mammalian cell culture is at the core of bio manufacturing therapeutic \n proteins and viral vaccines. Cells isolated from animal tissues can be \n expanded in culture for use as a research tool for the production of \n virus vaccines and various therapeutic proteins, and to generate \n functional cells or tissue analogues for regenerative medicine. In the \n past quarter century, cells derived from animals, especially mammals, \n have become a major vehicle for producing biologics, a class of \n medications that includes vaccines and various proteins used in treating \n cancer, genetic diseases, and other ailments.\n \n \n Mammalian cells can be made to produce vaccines through viral infection \n and therapeutic proteins through genetic engineering. Many of these \n medicines are necessary for patients who either lack the normal form of \n a protein or cannot produce it in sufficient quantity. Other therapeutic \n proteins include antibodies and specific binding proteins that \n neutralize disease-causing molecules within the body. Human cells, in \n particular, are poised to enable opportunities in cell-based therapy and \n regenerative medicine. The technology that exists now can derive stem \n cells from many sources and guide them to beco...